Boston, September 9, 2019 – MarketsandMarkets recently interviewed Elodie Baumfeld Andre, Senior Director, Epidemiology Strategy Lead, Worldwide Medical & Safety, Pfizer regarding 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress taking place on October 24 – 25, 2019 at DoubleTree by Hilton Boston-Downtown .
Elodie Baumfeld Andre is the Epidemiology Strategy Lead within the Worldwide Medical & Safety group at Pfizer. In this role, Elodie’s focus is on generating Real World Evidence (RWE) to support regulatory decision-making and driving continued innovation by implementing novel clinical designs and developing operating models. She is involved in discussions with global regulatory authorities, academics and focus groups to share learnings in this evolving space
Q. How will recent changes in the regulatory landscape help in better real-world evidence generation?
A. “Regulators implementing programs designed to drive/incorporate the application of real-world evidence, together with an increase in the availability of data and significant advancements in data analysis capabilities, has the potential to make our development process more efficient. This will ultimately help physicians and patients make better informed decisions.
Q. How important is Artificial Intelligence in real-world evidence for drug development?
A. “The creation of large data lakes which aggregate information from different real-world data sources, has opened the door for greater use of artificial intelligence and machine learning approaches to identify clinically meaningful patterns which in turn, can have a profound impact on breakthrough discoveries and patients.”
Q. Having gone through the agenda, what are your views on it and how helpful it is to the targeted audience?
A. “The 2nd Annual Real-World Data and Life Science Analytics Congress agenda, is providing the right balance between strategic and methodologic considerations, which should generate interesting points of discussion among panelists and participants and ultimately, advance the real-world evidence conversation in the context of drug development and regulatory decision-making.”
Elodie Baumfeld Andre is one of the panelists for a discussion on “Pros & Cons of Real-World Evidence framework by FDA. Perspective from different stakeholders provides & payers” along with Nneka Onwudiwe, Charles Makin, Jeremy Rassen.
The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2kChqXS
For more inquiries contact Amit Shelke, Marketing Manager on email@example.com